CRC subtype 3 turned out to be enriched for tumors with BRAF mutations (33% of cases versus 5% in the other CRC samples; S7 Table) and MSI tumors (30% of cases versus 1% in the other CRC samples). Here, BRAF is linked to colorectal carcinoma.